|
May 9
|
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
|
|
May 8
|
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
|
|
May 7
|
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 7
|
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 2
|
Why Earnings Season Could Be Great for Arvinas (ARVN)
|
|
May 2
|
Arvinas to Present at Upcoming Investor Conferences
|
|
May 1
|
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Apr 30
|
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
|
Apr 26
|
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 24
|
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
|
|
Apr 12
|
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
|
|
Apr 11
|
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
|
|
Apr 11
|
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
|
|
Apr 11
|
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
|
|
Apr 9
|
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
|
|
Mar 18
|
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
|
|
Mar 4
|
Arvinas to Participate in Upcoming Investor Conferences
|
|
Feb 14
|
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
|
|
Jan 16
|
Arvinas Appoints Jared Freedberg as General Counsel
|
|
Jan 1
|
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?
|